December 13, 2001 — ATLANTA, GA — Serologicals Corporation has completed its previously announced acquisition of the Intergen Company, a privately owned supplier of biological products and technologies to the life sciences industry.
Under the terms of the agreement, Serologicals acquired Intergen for $45 million in cash, less the amounts necessary to complete the expansion of Intergen’s Toronto manufacturing facility. The previous owners of Intergen are also eligible for additional compensation dependent upon the successful commercialization of certain Intergen products and technologies.
“We are extremely delighted to have completed the acquisition of Intergen, and both organizations are now diligently focusing on the integration process,” said David A. Dodd, president CEO of Serologicals Corporation. “Bringing together these highly innovative and focused companies will provide the life sciences industry with an expanded portfolio of biopharmaceutical products and platform technologies, targeting the rapidly growing cell culture media, biological components and life science enabling technology markets.”
Serologicals Corporation is a worldwide provider of biological products to life science companies. The company’s products are used in the further development of diagnostic, biotech and therapeutic products.